Medivation (MDVN +3.4%) moves up today after its Japanese alliance partner Astellas Pharma...
Friday, February 1, 12:20 PM ETMedivation (MDVN +3.4%) moves up today after its Japanese alliance partner Astellas Pharma reported in its financial results last night that it expects Xtandi sales to exceed year-end net sales targets ending on March 31. MDVN is due to report at the end of February. Separately, Jefferies raises its price target on the shares from $62 to $64.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles